BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

The heavy reliance of Italy’s biotech sector on academic labs and angel investors could result in many companies facing existential risk during the coronavirus outbreak. If they can hang on, the silver lining is that...
BC Week In Review | Mar 3, 2014
Clinical News

EryDex: Additional Phase II data

Additional data from an open-label, Italian Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia showed that monthly EryDex encapsulated in autologous erythrocytes reduced mean total ICAR score from baseline to 6 months, the...
BC Extra | Aug 1, 2013
Financial News

EryDel raises EUR 15 million in B round

EryDel S.p.A (Urbino, Italy) raised EUR 15 million ($19.9 million) in a series B round led by new investor Genextra S.p.A. , with participation from existing investors Innogest and Focus Gestioni. Genextra's CEO Lorenzo Tallarigo will...
BC Week In Review | Mar 5, 2012
Clinical News

EryDex: Phase II data

An open-label, Italian Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia showed that monthly EryDex encapsulated in autologous erythrocytes met the primary endpoint of reducing total ICARS score from baseline to 6 months...
BC Extra | Mar 1, 2012
Clinical News

EryDel's EryDex meets Phase II endpoint

EryDel S.p.A. (Urbino, Italy) said EryDex encapsulated in autologous erythrocytes met the primary endpoint in a Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia. The product significantly reduced the total International Cooperative Ataxia...
Items per page:
1 - 5 of 5